For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of this treatment and Attruby represents a genuine breakthrough . These novel therapies preserve the transthyretin protein, preventing its damaging build-up and reducing the burd